WallStreetZenWallStreetZen

NASDAQ: ALEC
Alector Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALEC

Based on 1 analyst offering 12 month price targets for Alector Inc

Min Forecast
$6.00+150%
Avg Forecast
$6.00+150%
Max Forecast
$6.00+150%

Should I buy or sell ALEC stock?

Based on 2 analysts offering ratings for Alector Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALEC's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ALEC as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their ALEC stock forecasts and price targets.

ALEC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-15
lockedlocked$00.00+00.00%2026-03-10

1 of 1

Forecast return on equity

Is ALEC forecast to generate an efficient return?

Forecast return on assets

Is ALEC forecast to generate an efficient return on assets?

Company
-37.34%
Industry
23.21%
ALEC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALEC earnings per share forecast

What is ALEC's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.93
Avg 2 year Forecast
-$0.72
Avg 3 year Forecast
-$0.77

ALEC revenue forecast

What is ALEC's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$11.2M-19.14%
Avg 2 year Forecast
$42.7M+208.08%
Avg 3 year Forecast
$15.0M+8.55%
ALEC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ALEC revenue growth forecast

How is ALEC forecast to perform vs Biotechnology companies and vs the US market?

Company
24.7%
Industry
31.33%
Market
13.34%
ALEC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ALEC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ALEC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALEC$2.40$6.00+150.00%Strong Buy
YDES$3.78N/AN/A
AVXL$2.87$24.00+736.24%Strong Buy
ZNTL$3.71$9.00+142.59%Strong Buy
WHWK$4.63$9.00+94.38%Strong Buy
View Top Biotech Stocks

Alector Stock Forecast FAQ

Is Alector Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ALEC) stock is to Strong Buy ALEC stock.

Out of 2 analysts, 2 (100%) are recommending ALEC as a Strong Buy, 0 (0%) are recommending ALEC as a Buy, 0 (0%) are recommending ALEC as a Hold, 0 (0%) are recommending ALEC as a Sell, and 0 (0%) are recommending ALEC as a Strong Sell.

If you're new to stock investing, here's how to buy Alector stock.

What is ALEC's earnings growth forecast for 2026-2028?

(NASDAQ: ALEC) Alector's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.

Alector's earnings in 2026 is -$117,854,000.On average, 10 Wall Street analysts forecast ALEC's earnings for 2026 to be -$103,416,638, with the lowest ALEC earnings forecast at -$111,612,256, and the highest ALEC earnings forecast at -$98,481,403. On average, 10 Wall Street analysts forecast ALEC's earnings for 2027 to be -$79,912,857, with the lowest ALEC earnings forecast at -$103,952,592, and the highest ALEC earnings forecast at -$46,895,906.

In 2028, ALEC is forecast to generate -$85,986,993 in earnings, with the lowest earnings forecast at -$106,141,067 and the highest earnings forecast at -$53,930,292.

What is ALEC's revenue growth forecast for 2026-2028?

(NASDAQ: ALEC) Alector's forecast annual revenue growth rate of 24.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.34%.

Alector's revenue in 2026 is $13,863,000.On average, 10 Wall Street analysts forecast ALEC's revenue for 2026 to be $1,251,674,062, with the lowest ALEC revenue forecast at $587,203,737, and the highest ALEC revenue forecast at $2,344,795,299. On average, 10 Wall Street analysts forecast ALEC's revenue for 2027 to be $4,768,755,354, with the lowest ALEC revenue forecast at $547,118,903, and the highest ALEC revenue forecast at $18,500,434,909.

In 2028, ALEC is forecast to generate $1,680,213,317 in revenue, with the lowest revenue forecast at $547,118,903 and the highest revenue forecast at $3,218,510,690.

What is ALEC's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ALEC) forecast ROA is -37.34%, which is lower than the forecast US Biotechnology industry average of 23.21%.

What is ALEC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ALEC price target, the average ALEC price target is $6.00, with the highest ALEC stock price forecast at $6.00 and the lowest ALEC stock price forecast at $6.00.

The Wall Street analyst predicted that Alector's share price could reach $6.00 by Apr 15, 2027. The average Alector stock price prediction forecasts a potential upside of 150% from the current ALEC share price of $2.40.

What is ALEC's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ALEC) Alector's current Earnings Per Share (EPS) is -$1.10. On average, analysts forecast that ALEC's EPS will be -$0.93 for 2026, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.88. On average, analysts forecast that ALEC's EPS will be -$0.72 for 2027, with the lowest EPS forecast at -$0.93, and the highest EPS forecast at -$0.42. In 2028, ALEC's EPS is forecast to hit -$0.77 (min: -$0.95, max: -$0.48).

What is ALEC's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ALEC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.